News & Updates

The use of tumour necrosis factor-α inhibitor (TNFi) for inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) raises the risk of developing psoriasis by twofold as compared with conventional therapy, although the absolute risk remains modest, as reported in a study.

In the treatment of patients with acne vulgaris, the investigational peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) 5% gel appears to help clear lesions and improve acne severity while being safe, according to the results of a phase IIb study.

Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.